1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • September 2016
  • 155 pages
  • ID: 4162565
  • Format: PDF
  • By BCC Research

Summary

Table of Contents

Use this report to:
- Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole
- Identify important trends and provide sales forecasts by product categories and major country markets through 2021
- Study epidemiological data, projections and information on R&D trends, and market potential on a country-by-country basis
- Evaluate the devices and instruments used for the diagnosis and monitoring of diabetes

Highlights
- The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.
- The oral hypoglycemic drugs market should reach $88 billion by 2021 from $67 billion in 2016 at a CAGR of 5.6%, from 2016 to 2021.
- The monitoring devices and accessories market should reach $17 billion by 2021 from $11 billion in 2016 at a CAGR of 9.1%, from 2016 to 2021.

Introduction & Scope

STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes, as well as the devices and instruments used for diagnosis and monitoring of diabetes. Special emphasis is given to the major forces contributing to the vigorous growth of the diabetes market. The report identified important trends and provides sales forecasts by product categories and major country markets through 2021; these are based on epidemiological data and projections, plus information on R&D trends and market potential on a country-by-country basis. Healthcare policies, demographics and the wider economic environment are also taken into account.

REASONS FOR DOING THE STUDY
It is widely recognized that the prevalence of the most common type of diabetes mellitus, type 2, is now reaching epidemic proportions all over the world. Cases of type 1 diabetes mellitus are also on the increase, although to a lesser degree. These trends are of great concern, not only to the individuals concerned, but also to governments and providers of healthcare, because the economic consequences of diabetes are vast. They involve not only the direct burden of managing the disease but also its common and often catastrophic complications, including cardiovascular disease, peripheral neuropathy and blindness. Prompt diagnosis and effective treatment of diabetes are not optional but essential priorities for governments and healthcare agencies. The already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence significance to the suppliers of the drugs used in treatment of the disease and the devices needed for monitoring. The information needs of companies in this field include accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next five years, and the impact of drugs and technical developments now in the pipeline.

SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country. A comprehensive refresher section on diabetes is provided as an appendix.

MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2016-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories discussed include insulins and oral hypoglycemic agents, devices such as blood glucose monitors and accessories, and software aids to self-management of the disease by diabetics.

METHODOLOGY
Primary research includes interviews with leading individuals in relevant companies and medical associations, and primary sources of published data, including epidemiological and economic studies, company annual reports, SEC filings and government publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC Research.

INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. It is also aimed at managers and executives in marketing, research, planning and sales departments who need comprehensive and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES
Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Corporate annual reports and SEC filings, journal articles and data from healthcare institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019SummaryTyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental ...

Glucokinase - Pipeline Review, H2 2019

Glucokinase - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Glucokinase - Pipeline Review, H2 2019SummaryGlucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the ...

Islet Amyloid Polypeptide - Pipeline Review, H1 2020

Islet Amyloid Polypeptide - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Islet Amyloid Polypeptide - Pipeline Review, H1 2020SummaryIslet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 12 ...

Incretion Drugs Markets in China $ 4000 October 2019


ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on